{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DOSE+formulation",
    "query": {
      "intervention": "DOSE formulation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1652,
    "total_pages": 166,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DOSE+formulation&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T12:43:39.875Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02779829",
      "title": "18432-Sun Protection Factor Assay",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sunscreening Agent"
      ],
      "interventions": [
        {
          "name": "Coppertone (BAY 987517)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 13,
      "start_date": "2015-07-29",
      "completion_date": "2015-09-01",
      "has_results": false,
      "last_update_posted_date": "2018-12-12",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 1,
      "location_summary": "Union, New Jersey",
      "locations": [
        {
          "city": "Union",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02779829"
    },
    {
      "nct_id": "NCT05683249",
      "title": "Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "NRCT-101-SR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocentria, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 223,
      "start_date": "2023-02-25",
      "completion_date": "2024-01-17",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 9,
      "location_summary": "Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05683249"
    },
    {
      "nct_id": "NCT01457430",
      "title": "Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Icatibant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2011-12",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-10-18",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wheaton",
          "state": "Maryland"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01457430"
    },
    {
      "nct_id": "NCT03828084",
      "title": "Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EpiDestiny, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2019-04-03",
      "completion_date": "2019-05-03",
      "has_results": false,
      "last_update_posted_date": "2019-05-09",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03828084"
    },
    {
      "nct_id": "NCT02382640",
      "title": "Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Febuxostat XR",
          "type": "DRUG"
        },
        {
          "name": "Maalox Advance Regular Strength liquid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2015-03",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-04-29",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02382640"
    },
    {
      "nct_id": "NCT01648179",
      "title": "A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Bacterial"
      ],
      "interventions": [
        {
          "name": "GSK1322322 (mesylate salt) Powder for Injection",
          "type": "DRUG"
        },
        {
          "name": "GSK1322322 (freebase) tablets",
          "type": "DRUG"
        },
        {
          "name": "GSK1322322 (mesylate salt) Powder for Oral Solution",
          "type": "DRUG"
        },
        {
          "name": "GSK1322322 (freebase) tablets FED",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2012-03",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2017-03-22",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01648179"
    },
    {
      "nct_id": "NCT05565950",
      "title": "AI-09 In Subjects With Glabellar Lines, GL-101",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glabellar Frown Lines"
      ],
      "interventions": [
        {
          "name": "AI-09",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vehicle",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eirion Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "20 Years to 70 Years"
      },
      "enrollment_count": 96,
      "start_date": "2022-10-03",
      "completion_date": "2024-05-22",
      "has_results": true,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 4,
      "location_summary": "Boca Raton, Florida • Miami, Florida • New Brighton, Minnesota + 1 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New Brighton",
          "state": "Minnesota"
        },
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05565950"
    },
    {
      "nct_id": "NCT00510874",
      "title": "Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Pumarix™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pandemrix ™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 780,
      "start_date": "2007-07-28",
      "completion_date": "2008-10-24",
      "has_results": true,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 7,
      "location_summary": "Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00510874"
    },
    {
      "nct_id": "NCT01427582",
      "title": "YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Trabectedin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-09-01",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01427582"
    },
    {
      "nct_id": "NCT02014103",
      "title": "Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Complication of Transplant"
      ],
      "interventions": [
        {
          "name": "Prograf",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus, Sandoz",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus, Reddy Laboratory",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus, Mylan",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus, Accord",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus, Pancea Biotech Limited",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2015-03",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-09-05T12:43:39.875Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02014103"
    }
  ]
}